SCHEMBL7256189

SCHEMBL7256189

CC(=O)Nc1ccc2c(c1)[nH]c1cc(O)ccc12

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 2/20 0.65
MAOA P21397 1/20 0.62
KDM4E B2RXH2 3/20 0.59
KMT2A Q03164 2/20 0.59
MTNR1A P48039 2/20 0.59
MTNR1B P49286 2/20 0.59
ERCC1 P07992 2/20 0.57
FEN1 P39748 2/20 0.57
ERCC4 Q92889 2/20 0.57
ALDH1A1 P00352 4/20 0.55
MAPT P10636 2/20 0.55
MEN1 O00255 1/20 0.55
CA12 O43570 1/20 0.55
BRD4 O60885 1/20 0.55
NR1I2 O75469 1/20 0.55
CA1 P00915 1/20 0.55
CA2 P00918 1/20 0.55
MB P02144 1/20 0.55
CYP1A1 P04798 1/20 0.55
CA3 P07451 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7108858 0.92 KDM4E (0.71) KIF11MAOAKDM4EKMT2AMTNR1A
SCHEMBL28022464 0.85 KIF11 (0.48) KIF11MAOAKDM4EKMT2AMTNR1A
SCHEMBL22616930 0.84 MAOA (0.86) KIF11MAOAKDM4EKMT2AMTNR1A
SCHEMBL28930131 0.80 KDM4E (0.67) KIF11MAOAKDM4EKMT2AMTNR1A
SCHEMBL1180474 0.80 JAK2 (0.50) KIF11MAOAKDM4EKMT2AMTNR1A
SCHEMBL13394668 0.80 ALDH1A1 (0.47) KIF11MAOAKDM4EKMT2AALDH1A1
SCHEMBL23165587 0.79 KMT2A (0.65) KIF11MAOAKDM4EKMT2AMTNR1A
SCHEMBL29760304 0.79 KMT2A (0.65) KIF11MAOAKDM4EKMT2AMTNR1A
SCHEMBL26362351 0.78 KIF11 (0.48) KIF11MAOAKDM4EKMT2AMTNR1A
SCHEMBL124178 0.76 KDM4E (0.57) KDM4EKMT2AALDH1A1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030040538-A1 Novel substituted tricyclic compounds ASAHI-KASEI KABUSHIKI KAISHA (JP) 2003-02-27 US disclosed
EP-1238973-A1 NOVEL SUBSTITUTED TRICYCLIC COMPOUNDS Asahi Kasei Kabushiki Kaisha (JP) 2002-09-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030040538-A1 Novel substituted tricyclic compounds CPT1A, CBR1, NR1H3 KIF11 4358/4885MAOA 2743/4885KDM4E 1429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.